2024
Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial
Laine L, Spechler S, Yadlapati R, Schnoll-Sussman F, Smith N, Leifke E, Harris T, Hunt B, Fass R, Katz P. Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial. Clinical Gastroenterology And Hepatology 2024, 22: 2211-2220.e10. PMID: 38750866, DOI: 10.1016/j.cgh.2024.05.004.Peer-Reviewed Original ResearchNon-erosive reflux diseaseHeartburn-free daysErosive esophagitisReflux diseaseRandomized trialsActive-treatment extensionRandomized to placeboPotassium-competitive acid blockerPlacebo-controlled periodDays of therapyPercentage of subjectsPrimary endpointPercentage of daysHeartburn symptomsPlaceboVonoprazanAcid blockerNighttime heartburnDay 1Randomized subjectsDocumented efficacyStudy armsDay 2Adult subjectsExtension period
2023
Retinal Ischemic Perivascular Lesions in Individuals With Atrial Fibrillation
Bakhoum C, Madala S, Lando L, Yarmohammadi A, Long C, Miguez S, Chan A, Singer M, Jin A, Steren B, Adabifirouzjaei F, Goldbaum M, DeMaria A, Sarraf D, Bakhoum M. Retinal Ischemic Perivascular Lesions in Individuals With Atrial Fibrillation. Journal Of The American Heart Association 2023, 12: e028853. PMID: 37577936, PMCID: PMC10492933, DOI: 10.1161/jaha.122.028853.Peer-Reviewed Original ResearchConceptsOptical coherence tomography scansAtrial fibrillationPerivascular lesionsTomography scanSpectral domain optical coherence tomography scansMacular spectral-domain optical coherence tomographySpectral-domain optical coherence tomographyMultivariable logistic regression modelCardiovascular risk factorsDomain optical coherence tomographyAtrial fibrillation groupCoronary artery diseaseIschemic heart diseaseSex-matched individualsCase-control studyPercentage of subjectsIschemic cardiovascular diseaseOptical coherence tomographyLogistic regression modelsCardiovascular workupCardiac emboliFibrillation groupSmoking historyArtery diseaseCarotid stenosis
2022
Simplified and more sensitive criteria for identifying individuals with pathogenic CDH1 variants
Lerner BA, Xicola RM, Rodriguez NJ, Karam R, Llor X. Simplified and more sensitive criteria for identifying individuals with pathogenic CDH1 variants. Journal Of Medical Genetics 2022, 60: 36-40. PMID: 35078942, PMCID: PMC9661780, DOI: 10.1136/jmedgenet-2021-108169.Peer-Reviewed Original ResearchConceptsInternational Gastric Cancer Linkage ConsortiumHereditary diffuse gastric cancerPercentage of subjectsGastric cancerMutation carriersPathogenic variantsMultigene panel testingPathogenic CDH1 variantsAutosomal dominant syndromeDiffuse gastric cancerClinical criteriaConsecutive casesMedical historyPathology reportsCDH1 variantsPanel testingGenetic testingCancer pathology reportsCancerPathology
2012
Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients
Tetrault JM, Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. Journal Of Substance Use And Addiction Treatment 2012, 43: 433-439. PMID: 22938914, DOI: 10.1016/j.jsat.2012.07.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineBuprenorphine, Naloxone Drug CombinationCounselingDelivery of Health Care, IntegratedFeasibility StudiesFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPsychotherapy, BriefSubstance Abuse DetectionTime FactorsTreatment OutcomeViral LoadConceptsEnhanced medical managementPhysician managementDetectable HIV viral loadHIV treatment settingsOpioid-negative urinesBuprenorphine/naloxoneHIV viral loadOpioid-dependent patientsPercentage of subjectsUntreated opioid dependenceExtended counselingHIV clinicHIV outcomesBuprenorphine/Medical managementOpioid dependenceViral loadDependent patientsExtensive counselingClinical trialsContinuous abstinenceNegative urineTreatment settingsGroup differencesCounseling
2010
STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects
Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects. Diabetes Technology & Therapeutics 2010, 12: 249-255. PMID: 20210562, PMCID: PMC2883476, DOI: 10.1089/dia.2009.0145.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous subcutaneous insulin infusionType 1 diabetesPercentage of subjectsPump therapyEnd pointBaseline characteristicsDaily injectionsKey safety end pointsType 1Sensor-Augmented Pump TherapyReal-time continuous glucose monitoringSensor-Augmented Insulin Pump TherapyNormal glycemic rangeTertiary end pointPrimary end pointSafety end pointSecondary end pointsInsulin pump therapySubcutaneous insulin infusionYears of treatmentContinuous glucose monitoringMDI cohortSevere hypoglycemiaClinical outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply